Furthermore, studies utilizing CTLA-4-Ig (abatacept) to treat type 1 diabetes and rheumatoid arthritis have shown a reduction in the frequency of CD4+ Tregs in these patients (56, 57). The gene discussed is CD4; the disease is type 1 diabetes mellitus.